维吾尔族妇女高危型HPV感染与免疫功能的相关性研究
本文选题:人乳头瘤病毒 + 宫颈病变 ; 参考:《新疆大学》2017年硕士论文
【摘要】:目的:宫颈癌是新疆维吾尔族妇女发病率极高的恶性肿瘤之一。利用分子生物学和免疫检测法,分析维吾尔族妇女高危型HPV感染的情况及危险因素;探讨维吾尔族妇女高危型HPV感染与多项免疫指标的变化及血清抗体水平之间的相关性,为建立宫颈癌筛查的辅助指标体系提供了依据。方法:2015年12月至2016年12月就诊于新疆维吾尔自治区人民医院门诊或住院的妇女,自愿接受HCII法检测HPV感染联合或者未联合液基细胞学检查,从中筛选出HPV感染阳性或者液基细胞学诊断≥非典型鳞状上皮细胞(atypical squamous cell of Undetermined signification,ASC-US)患者,进一步进行阴道镜下检查和活检送病理检查;同时抽取静脉血3~5毫升,分离出2毫升用于流式细胞仪法检测T淋巴细胞亚群;剩余的血清/血浆利用酶联免疫吸附法(ELISA)检测人乳头瘤病毒16型L1-IgG抗体水平。结果:1.(1)维吾尔族与汉族宫颈癌HPV阳性率分别为87.93%、68.04%;两民族之间有显著性差异(P0.01)。(2)HPV载量RLU/CO≥1.0为阳性,1.0为阴性,根据HPV载量高低分为1、1~100、100~1000、1000共4个载量组;宫颈病变与HPV载量(RLU/CO)之间存在正相关关系,HPV载量越高,宫颈病变程度越重(P0.01)。(3)维吾尔族和汉族两组中,HPV阴性(RLU/CO1)组分别与1~100组、100~1000组、1000组;且1~100组和1000组;100~1000组和1000组,各组间有显著性差异(P0.05)。(4)液基细胞学(TCT)检查结果分为宫颈上皮内病变阴性(NILM)、非典型鳞状上皮细胞(ASC-US)、低级别宫颈鳞状上皮内病变(LSIL)、高级别宫颈鳞状上皮内病变(HSIL)、宫颈鳞状细胞癌和非典型腺细胞(SCC+AGUS)等5个组;NILM、ASC-US、LSIL、HSIL、SCC+AGUS组与HPV阳性率两组之间有显著性差异(P0.01)。(5)在NILM组和SCC+AGUS组,汉族患者所占30.77%(4/13)、而维吾尔族患者所占69.23%(9/13),两组之间有显著性差异(P0.01)。(6)年龄和HPV载量也逐步升高,35~45岁和45~55岁之间明显升高(P0.05)。(7)宫颈病变与年龄有一定的关系,两组之间有显著性差异(P0.05)。2.(1)CD4辅助/诱导T细胞百分比参考范围33%~58%,根据参考范围高低分为33、33~45、45~58、58等4个组;随着宫颈病变程度的加重,CD4辅助/诱导T细胞百分比在33、33~45范围内明显下降,各组之间有显著性差异(P0.01)。(2)CD4/CD8比值参考范围0.71~2.78,根据参考范围高低分为0.71、0.71~1.74、1.74~2.78、2.78等4个组;随着宫颈病变程度的加重,CD4/CD8比值在0.71、0.71~1.74范围内明显下降,各组之间有显著性差异(P0.01)。(3)CD3总T细胞百分比参考范围56%~86%,根据参考范围高低分为56、56~71、71~86、86等4个组;随着宫颈病变的加重,CD3总T细胞百分比56~71、71~86范围有下降趋势,但差异无统计学意义(P0.05)。(4)CD8抑制/杀伤T细胞百分比参考范围13%~39%,根据参考范围高低分为13、13~26、26~39、39等4个组;随着宫颈病变的加重,CD8抑制/杀伤T细胞百分比39范围有下降趋势,但差异无统计学意义(P0.05)。3.(1)随着宫颈病变加重,HPV 16 L1-IgG抗体水平下降趋势,但各组之间无显著差异(P0.05)。(2)HPV载量(RLU/CO)不同的与HPV 16 L1-IgG抗体水平无显著性差异(P0.05)。(3)HPV16 L1-IgG抗体水平与不同民族之间没有相关性(P0.05)。(4)HPV16 L1-IgG抗体水平与年龄之间没有相关性(P0.05)。结论:1.宫颈病变级别与HR-HPV感染率呈正相关。HPV载量增加与高级别宫颈上皮内病变和宫颈癌的患病风险正相关。随着细胞学及宫颈病变病理学级别的升高,HR-HPV载量及HPV的阳性率均随之升高。2.机体免疫功能低下和免疫功能紊乱均使宫颈病变的危险度增高。高级别宫颈病变患者的细胞免疫功能均有不同程度的降低,其中宫颈癌患者的细胞免疫功能降低最为显著。3.血清HPV16 L1-IgG抗体检测阳性既可代表现存HPV感染,也可表示既往HPV感染。HPV 16 L1-IgG抗体阳性率随宫颈病变级别增高呈下降趋势,但血清抗体水平之间无显著性差异,试验结果可能与HPV清除与宫颈病变逆转有关。
[Abstract]:Objective: cervical cancer is one of the malignant tumors of Uygur women in Xinjiang. Using molecular biology and immunoassay, the situation and risk factors of high risk HPV infection in Uygur women are analyzed, and the correlation between high risk HPV infection of Uygur women and the changes of multiple immune markers and the level of serum antibody are discussed. To establish a basis for establishing an auxiliary index system for screening for cervical cancer. Methods: from December 2015 to December 2016, women who were hospitalized at the the Xinjiang Uygur Autonomous Region people's hospital were admitted to the the Xinjiang Uygur Autonomous Region people's hospital. The HPV infection combined with or without the combined liquid based cytological examination was tested voluntarily, and the positive or liquid based cytological diagnosis of HPV infection was screened out. Patients with atypical squamous cells (atypical squamous cell of Undetermined signification, ASC-US) were further examined under colposcopy and biopsy, and 3~5 milliliters of venous blood were extracted at the same time, and 2 ml was isolated for the detection of T lymphatic subsets by flow cytometry; the remaining serum / plasma was used for enzyme linked immunosorbent assay. Method (ELISA) detection of human papillomavirus type 16 L1-IgG antibody level. Results: 1. (1) the Uygur and Han cervical cancer HPV positive rate is 87.93%, 68.04%; two ethnic groups have significant difference (P0.01). (2) HPV load RLU/CO > 1 as positive, 1 as negative, according to the HPV load level is divided into 1,1~100100~10001000, 4 load groups; cervical disease There was a positive correlation between change and HPV load (RLU/CO), the higher the load of HPV, the higher the degree of cervical lesions (P0.01). (3) in two groups of Uygur and Han, HPV negative (RLU/CO1) group was respectively with 1~100 group, 100~1000 group and 1000 groups, and 1~100 group and 1000 group, 100~1000 group and 1000 groups, there were significant differences (P0.05). (4) liquid based cytology (TCT) examination The results were divided into 5 groups: negative cervical intraepithelial lesion (NILM), atypical squamous epithelial cell (ASC-US), low grade cervical squamous intraepithelial lesion (LSIL), high grade cervical squamous intraepithelial lesion (HSIL), cervical squamous cell carcinoma and atypical gland cell (SCC+AGUS), and NILM, ASC-US, LSIL, HSIL, SCC+AGUS group and HPV positive rate two groups Significant difference (P0.01). (5) in group NILM and group SCC+AGUS, 30.77% (4/13) of Han patients and 69.23% (9/13) of Uygur patients (9/13), there was a significant difference between two groups (P0.01). (6) age and HPV load increased gradually, 35~45 and 45~55 (P0.05). (7) there was a certain relationship between cervical lesions and age, two groups between the two groups. There were significant differences (P0.05).2. (1) CD4 auxiliary / inducement of T cell percentage reference range 33%~58%, according to the reference range of 33,33~45,45~58,58 and other groups, with the severity of cervical lesions, the percentage of CD4 assisted / induced T cells decreased significantly in the 33,33~45 range, there was a significant difference between each group (P0.01). (2) CD4/CD8 ratio reference. The range of 0.71~2.78 was divided into 4 groups according to the reference range of 0.71,0.71~1.74,1.74~2.78,2.78. With the aggravation of the degree of cervical lesions, the CD4/CD8 ratio decreased significantly within the range of 0.71,0.71~1.74. There was a significant difference between each group (P0.01). (3) the reference range of the total CD3 T cell percentage was 56%~86%, according to the reference range, 56,56~71,71 was divided into 56,56~71,71 ~86,86 and other 4 groups, with the aggravation of cervical lesions, the percentage of CD3 T cell percentage 56~71,71~86 decreased, but the difference was not statistically significant (P0.05). (4) the reference range of CD8 inhibition / killing T cell percentage was 13%~39%, according to the reference range, 4 groups were divided into 13,13~26,26~39,39 and so on. With the aggravation of cervical lesions, CD8 inhibition / killing T cells There was a downward trend in the percentage 39 range, but the difference was not statistically significant (P0.05).3. (1) with the aggravation of cervical lesions, HPV 16 L1-IgG antibody level decreased, but there was no significant difference between each group (P0.05). (2) there was no significant difference between HPV load (RLU/CO) and HPV 16 L1-IgG antibody water level (P0.05). (3) HPV16 L1-IgG antibody level and different ethnic groups. There is no correlation between (P0.05). (4) there is no correlation between HPV16 L1-IgG antibody level and age (P0.05). Conclusion: the level of cervical lesions and HR-HPV infection rate is positively correlated with the increase of.HPV load and high level cervical intraepithelial lesion and the risk of cervical cancer. With the increase of cytology and the pathological grade of cervical lesions, HR-HPV The positive rate of load and HPV increased with the immune function of.2. and the disorder of immune function, the risk of cervical lesions increased. The cellular immune function of patients with high grade cervical lesions decreased in varying degrees, and the most significant reduction of cellular immune function in cervical cancer patients was.3. serum HPV16 L1-IgG antibody test positive It can not only represent the existing HPV infection, but also indicate that the positive rate of.HPV 16 L1-IgG antibody in the previous HPV infection is decreasing with the increase of cervical lesions, but there is no significant difference between the serum antibody level and the results of the test may be related to the clearance of HPV and the reversal of cervical lesions.
【学位授予单位】:新疆大学
【学位级别】:硕士
【学位授予年份】:2017
【分类号】:R737.33
【相似文献】
相关期刊论文 前10条
1 胡致平;林圣云;叶宝东;沈建平;周郁鸿;虞荣喜;;非血缘异基因外周血干细胞移植治疗高危型急性淋巴细胞白血病2例报道[J];中国实用内科杂志;2007年S1期
2 艾红云;罗建刚;;阳江市育龄妇女高危型HPV感染情况分析[J];赣南医学院学报;2014年02期
3 王琳,张乐萍;儿童高危型急性淋巴细胞白血病复发危险因素及预后分析[J];中国实用儿科杂志;2003年03期
4 刘东玲;梁小勤;刘瑶;肖翠珍;金黎;;高危型HPV16/18感染在宫颈病变中的临床分析[J];广东医学;2008年04期
5 周小玲;黄瑾;;妊娠与高危型人乳头瘤病毒感染易感性的相关分析[J];中国优生与遗传杂志;2011年03期
6 李世霞;;515例妇女高危型HPV感染检测结果分析[J];中国肿瘤临床;2011年16期
7 胡慧仙;;高危型HPV在健康人群中的感染状况分析[J];中国现代药物应用;2013年20期
8 叶雪瑞;董瑞;李立群;谷鸿喜;商庆龙;;高危型人乳头瘤病毒基因组整合的研究进展[J];微生物与感染;2014年01期
9 刘润冰,安宏亮;146例妇女高危型HPV阳性检查结果分析[J];右江民族医学院学报;2004年02期
10 刘小平;高危型HPV阳性的处理[J];国外医学.妇产科学分册;2004年03期
相关会议论文 前10条
1 胡致平;林圣云;周郁鸿;虞荣喜;沈建平;叶宝东;罗秀素;沈一平;郑智茵;陈均法;俞庆红;庄海峰;;非血缘异基因外周血干细胞移植治疗高危型儿童急性淋巴细胞性白血病一例报道[A];2006年浙江省血液病学学术年会论文汇编[C];2006年
2 胡致平;林圣云;周郁鸿;虞荣喜;沈建平;叶宝东;罗秀素;沈一平;郑智茵;陈均法;俞庆红;庄海峰;;非血缘异基因外周血干细胞移植治疗高危型儿童急性淋巴细胞性白血病一例报道[A];2006年浙江省内科学学术年会、2006年浙江省老年医学学术年会论文汇编[C];2006年
3 岑坚敏;钱德英;王丁;曾仁海;舒焰红;洪淡华;黄志宏;林爱华;;高危型HPV检测对不典型鳞状细胞的分流监测价值[A];中华医学会第九次全国妇科肿瘤学术会议论文汇编[C];2006年
4 胡致平;林圣云;叶宝东;沈建平;周郁鸿;虞荣喜;;非血缘异基因外周血干细胞移植治疗高危型急性淋巴细胞白血病二例报道[A];第八届全国中西医结合血液病学术会议论文集[C];2007年
5 胡致平;林圣云;叶宝东;沈建平;周郁鸿;虞荣喜;;非血缘异基因外周血干细胞移植治疗高危型急性淋巴细胞白血病二例报道[A];浙江省中西医结合学会血液病专业委员会第二次学术年会暨省级继续教育学习班资料汇编[C];2007年
6 胡致平;林圣云;叶宝东;沈建平;周郁鸿;虞荣喜;;非血缘异基因外周血干细胞移植治疗高危型急性淋巴细胞白血病二例报道[A];2007年浙江省血液病学术年会论文汇编[C];2007年
7 胡致平;林圣云;周郁鸿;虞荣喜;沈建平;叶宝东;罗秀素;沈一平;郑智茵;陈均法;俞庆红;庄海峰;;非血缘异基因外周血干细胞移植治疗高危型儿童急性淋巴细胞性白血病一例报道[A];全国中西医结合血液病学术研讨会、浙江省中西医结合学会血液病专业委员会成立大会首次学术年会暨继续教育学习班论文汇编[C];2006年
8 欧阳敏珊;叶敦敏;;宫颈上皮内瘤变证型分布及与高危型HPV感染相关性的研究[A];第九次全国中医妇科学术大会论文集[C];2009年
9 沈云岳;刘华;王蕾;高锋;;高危型人乳头瘤病毒检测方法的评估[A];中华医学会第八次全国检验医学学术会议暨中华医学会检验分会成立30周年庆典大会资料汇编[C];2009年
10 张立冬;谢威;裴静;赵旦;;宫颈细胞学筛查及高危型HPV检测与宫颈组织学[A];中华医学会第十次全国妇产科学术会议妇科肿瘤会场(妇科肿瘤学组、妇科病理学组)论文汇编[C];2012年
相关重要报纸文章 前1条
1 记者 王丹;高危型人乳头瘤病毒DNA检测可用于宫颈癌初筛[N];健康报;2010年
相关博士学位论文 前5条
1 于露露;HPV16/18E6癌蛋白、p16/Ki-67表达与高危型HPV持续感染的关系及其在宫颈癌筛查中的应用评估[D];北京协和医学院;2016年
2 徐垲;“紫柏凝胶”治疗宫颈高危型HPV感染的临床与实验研究[D];北京中医药大学;2014年
3 郑闪;高危型人乳头瘤病毒(HPV-16/18)感染与人膀胱移行细胞癌关系[D];中国协和医科大学;2002年
4 张魏芳;高危型人乳头瘤病毒早期蛋白E6和E7调控细胞周期的机制研究[D];山东大学;2010年
5 张东红;高危型人乳头瘤病毒感染对食管癌不良预后的研究[D];北京协和医学院;2014年
相关硕士学位论文 前10条
1 孙浩罡;OPN、p53在宫颈病变组织中的表达与高危型HPV感染的相关性研究[D];石河子大学;2015年
2 赵晓梅;47例高危型妊娠滋养细胞肿瘤的临床资料分析[D];河北医科大学;2015年
3 刘静;高危型HPV持续感染与阴道局部黏膜免疫中免疫球蛋白的关系[D];天津医科大学;2015年
4 付杨;儿黄散膜剂治疗高危型HPV合并CINⅠ~Ⅱ级的临床观察[D];黑龙江中医药大学;2016年
5 张乾泉;遵义地区611例妊娠女性人乳头瘤病毒感染现状调查[D];遵义医学院;2016年
6 李英;煤矿女职工高危型人乳头瘤病毒感染特征及相关因素分析[D];山西医科大学;2016年
7 张丽霞;晋城地区机会性筛查人群高危型人乳头瘤病毒(HPV)感染水平及基因型分析[D];山西医科大学;2016年
8 崔曼;968例宫颈高危型HPV感染患者临床分析[D];吉林大学;2016年
9 梁培琴;宫颈高危型人乳头瘤病毒感染危险因素的研究[D];南方医科大学;2016年
10 潘萍;芪草二术散外治宫颈高危型HPV感染的疗效观察[D];南京中医药大学;2016年
,本文编号:1882525
本文链接:https://www.wllwen.com/yixuelunwen/zlx/1882525.html